BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adas G, Cukurova Z, Yasar KK, Yilmaz R, Isiksacan N, Kasapoglu P, Yesilbag Z, Koyuncu ID, Karaoz E. The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial. Cell Transplant 2021;30:9636897211024942. [PMID: 34180719 DOI: 10.1177/09636897211024942] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 24.0] [Reference Citation Analysis]
Number Citing Articles
1 Kirkham AM, Bailey AJ, Shorr R, Lalu MM, Fergusson DA, Allan DS. Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late? Cytotherapy 2022. [DOI: 10.1016/j.jcyt.2022.10.003] [Reference Citation Analysis]
2 Cao JX, You J, Wu LH, Luo K, Wang ZX. Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review. World J Clin Cases 2022; 10(27): 9714-9726 [DOI: 10.12998/wjcc.v10.i27.9714] [Reference Citation Analysis]
3 Balakrishna Pillai A, Mariappan V, JeanPierre AR, Rao SR. Restoration of vascular endothelial integrity by mesenchymal stromal/stem cells in debilitating virus diseases. Hum Cell 2022. [PMID: 36068397 DOI: 10.1007/s13577-022-00785-3] [Reference Citation Analysis]
4 Yao W, Dong H, Qi J, Zhang Y, Shi L. Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: A systematic review and meta-analysis. EClinicalMedicine 2022;51:101545. [PMID: 35844767 DOI: 10.1016/j.eclinm.2022.101545] [Reference Citation Analysis]
5 Huang Y, Li X, Yang L. Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment. Stem Cell Res Ther 2022;13:410. [PMID: 35962458 DOI: 10.1186/s13287-022-03034-4] [Reference Citation Analysis]
6 Aghayan HR, Salimian F, Abedini A, Fattah Ghazi S, Yunesian M, Alavi-Moghadam S, Makarem J, Majidzadeh-A K, Hatamkhani A, Moghri M, Danesh A, Haddad-Marandi MR, Sanati H, Abbasvandi F, Arjmand B, Azimi P, Ghavamzadeh A, Sarrami-Forooshani R. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment. Stem Cell Res Ther 2022;13:365. [PMID: 35902979 DOI: 10.1186/s13287-022-02953-6] [Reference Citation Analysis]
7 Abdullah M, Pawitan JA, Irawan C, - R, Aditianingsih D, Liem IK, Sinto R, Susilo A, Yulianti M, Handayani RRD, Pratomo IP, Burhan E, Damayanti T, Wibowo H, Dilogo IH, Muliawan HS, Elhidsi M. Effectiveness and safety profile of mesenchymal stem cell secretome as a treatment for severe cases of COVID-19: a randomized controlled trial. F1000Res 2022;11:143. [DOI: 10.12688/f1000research.75580.2] [Reference Citation Analysis]
8 Manoharan R, Kore RA, Mehta JL. Mesenchymal stem cell treatment for hyperactive immune response in patients with COVID-19. Immunotherapy 2022. [PMID: 35855633 DOI: 10.2217/imt-2021-0245] [Reference Citation Analysis]
9 Rossello-Gelabert M, Gonzalez-Pujana A, Igartua M, Santos-Vizcaino E, Hernandez RM. Clinical progress in MSC-based therapies for the management of severe COVID-19. Cytokine Growth Factor Rev 2022:S1359-6101(22)00050-8. [PMID: 35843774 DOI: 10.1016/j.cytogfr.2022.07.002] [Reference Citation Analysis]
10 Kirkham AM, Bailey AJM, Monaghan M, Shorr R, Lalu MM, Fergusson DA, Allan DS. Updated Living Systematic Review and Meta-analysis of Controlled Trials of Mesenchymal Stromal Cells to Treat COVID-19: A Framework for Accelerated Synthesis of Trial Evidence for Rapid Approval-FASTER Approval. Stem Cells Transl Med 2022:szac038. [PMID: 35758400 DOI: 10.1093/stcltm/szac038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Zhang M, Yan X, Shi M, Li R, Pi Z, Ren X, Wang Y, Yan S, Wang Y, Jin Y, Wang X. Safety and efficiency of stem cell therapy for COVID-19: a systematic review and meta-analysis. Glob Health Res Policy 2022;7:19. [PMID: 35733229 DOI: 10.1186/s41256-022-00251-5] [Reference Citation Analysis]
12 Javed A, Karki S, Sami Z, Khan Z, Shree A, Sah BK, Ghosh S, Saxena S, Chen H. Association between Mesenchymal Stem Cells and COVID-19 Therapy: Systematic Review and Current Trends. BioMed Research International 2022;2022:1-17. [DOI: 10.1155/2022/9346939] [Reference Citation Analysis]
13 Mönch D, Reinders MEJ, Dahlke MH, Hoogduijn MJ. How to Make Sense out of 75,000 Mesenchymal Stromal Cell Publications? Cells 2022;11:1419. [DOI: 10.3390/cells11091419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Karyana M, Djaharuddin I, Rif'ati L, Arif M, Choi MK, Angginy N, Yoon A, Han J, Josh F, Arlinda D, Narulita A, Muchtar F, Bakri RA, Irmansyah S. Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial. Stem Cell Res Ther 2022;13:134. [PMID: 35365239 DOI: 10.1186/s13287-022-02812-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Yao W, Shi L, Zhang Y, Dong H, Zhang Y. Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives. Stem Cell Res Ther 2022;13:124. [PMID: 35321737 DOI: 10.1186/s13287-022-02810-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Rebelatto CLK, Senegaglia AC, Franck CL, Daga DR, Shigunov P, Stimamiglio MA, Marsaro DB, Schaidt B, Micosky A, de Azambuja AP, Leitão CA, Petterle RR, Jamur VR, Vaz IM, Mallmann AP, Carraro Junior H, Ditzel E, Brofman PRS, Correa A. Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. Stem Cell Res Ther 2022;13:122. [PMID: 35313959 DOI: 10.1186/s13287-022-02796-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Xu R, Feng Z, Wang FS. Mesenchymal stem cell treatment for COVID-19. EBioMedicine 2022;77:103920. [PMID: 35279630 DOI: 10.1016/j.ebiom.2022.103920] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
18 Lu K, Geng ST, Tang S, Yang H, Xiong W, Xu F, Yuan Q, Xiao X, Huang R, Liang H, Chen Z, Qian C, Li Y, Wang S. Clinical efficacy and mechanism of mesenchymal stromal cells in treatment of COVID-19. Stem Cell Res Ther 2022;13:61. [PMID: 35130977 DOI: 10.1186/s13287-022-02743-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Abdullah M, Pawitan JA, Irawan C, - R, Aditianingsih D, Liem IK, Sinto R, Susilo A, Yulianti M, Handayani RRD, Pratomo IP, Burhan E, Damayanti T, Wibowo H, Dilogo IH. Effectiveness and safety profile of mesenchymal stem cell secretome as a treatment for severe cases of COVID-19: a randomized controlled trial. F1000Res 2022;11:143. [DOI: 10.12688/f1000research.75580.1] [Reference Citation Analysis]
20 Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B, Song J, Huang L, Xu Z, Fu JL, Li Y, Xu R, Li TT, Dong J, Cai J, Li G, Xie Y, Shi M, Li Y, Zhang Y, Xie WF, Wang FS. Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine 2021;75:103789. [PMID: 34963099 DOI: 10.1016/j.ebiom.2021.103789] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
21 Sanberg P, Morrison DC, Kovacs RA, Bjugstad K. A Retrospective Look at Recent COVID-19 Articles Published in Cell Transplantation: Research Leading to Further Understanding. Cell Transplant 2021;30:9636897211049814. [PMID: 34689578 DOI: 10.1177/09636897211049814] [Reference Citation Analysis]
22 Zhao Y, Yan Z, Liu Y, Zhang Y, Shi J, Li J, Ji F. Effectivity of mesenchymal stem cells for bleomycin-induced pulmonary fibrosis: a systematic review and implication for clinical application. Stem Cell Res Ther 2021;12:470. [PMID: 34420515 DOI: 10.1186/s13287-021-02551-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]